Together since 2007

Transforming money management to make financial markets accessible to all

Acquired since 2021

Enabling the human right of mobility to all

Acquired since 2017

Introducing Zero Trust mechanisms for a truly sale environment

Acquired since 1994

Introduced cyber security to the mass business market

Together since 2010

Harnessing the power of artificial vision to transform the lives of visually impaired

Together since 2020

Digital Learning Platform designed to optimize student engagement and learning outcome

Together since 2019

AI-driven end-to-end Fix & Flip platform

Together since 2021

First drone delivery service focused in the US suburbs.

Acquired by DG 2007

Global provider of digital advertising solutions that optimize the use of media, creative and data for enhanced performance.

Together since 2010

Leading investment house in Israel, managing over 77 Billion Dollars for private, business and institutional clients

Together since 2016

Developing and commercializing novel endovascular treatments for stroke

Together since 2012

Developing percutaneous implantable technologies for patients with chronic heart failure


March 5, 2020
CE Mark for the Ventura™ Interatrial Shunt System is a significant milestone for V-Wave, as it recognizes that this therapeutic product conforms to the standards of the European Medical Device Directive
V-Wave Ltd., a privately held medical device company developing novel implantable devices for the treatment of Heart Failure (HF), today announced that its Ventura™ Interatrial Shunt System received CE Mark and is now approved to be marketed for use in the European Union.

“More than 26 million people suffer from chronic heart failure worldwide, and HF remains a leading driver of disability and acute hospitalization, particularly in the growing elderly population,” noted V-Wave Chief Medical Officer and renowned heart failure cardiologist, William T. Abraham, MD. “Despite decades of advances, heart failure patients continue to progressively deteriorate, enduring disabling symptoms, having a poor quality of life, diminished exercise tolerance, and a markedly reduced life expectancy. The minimally invasive implanted Ventura Interatrial Shunt relieves excessive pressure in the left-side of the heart, thereby reducing the build-up of fluid in the lungs, which is the most common reason for worsening HF symptoms, exercise limitation, and HF hospitalizations.”

The Ventura Interatrial Shunt is being evaluated in a global, randomized, controlled, double-blinded, 500 patient U.S. Food and Drug Administration (FDA) IDE pivotal trial called RELIEVE-HF, which is designed to demonstrate safety and effectiveness of shunt therapy in reducing HF morbidity and mortality and improving functional status. The study is enrolling advanced HF patients with preserved or reduced left ventricular ejection fraction who remain symptomatic despite the use of guideline-directed medical and device therapies. Approximately 100 of the top hospitals in North America, Europe and Israel are or will be participating.

“CE mark for the Ventura Interatrial Shunt System is a significant milestone for V-Wave, as it recognizes that this therapeutic product conforms to the standards of the European Medical Device Directive,” said V-Wave CEO Neal Eigler, MD. “Along with the FDA Breakthrough Device Designations we received last year, CE Marking will help accelerate the introduction of our potentially impactful clinical treatment to the millions of patients suffering from heart failure.”

About V-Wave Ltd.
V-Wave is a privately held medical device company with offices in Israel and the U.S. In addition to developing interatrial shunt device technologies for the treatment of heart failure, V-Wave is exploring the use of such technologies for the treatment of Pulmonary Arterial Hypertension in an FDA IDE Early Feasibility Study. For more information, please visit

This press release contains certain forward-looking statements that involve risks and uncertainties, including statements related to clinical development and potential regulatory approval of V-Wave’s products. All forward-looking statements and other information included in this press release are based on information available to V-Wave as of the date hereof, and the Company assumes no obligation to update any such forward-looking statements or information. The company’s actual results could differ materially from those described in the company’s forward-looking statements.